



FOR IMMEDIATE RELEASE

CONTACT :

D. Lansing Taylor, Ph.D., President and CEO, Cellumen, 412- 481-5690
Lynn M. Brusco, Pittsburgh Life Sciences Greenhouse, 412 -770-1353

**Cellumen Uses Its Cellular Technology to Profile Toxins for the U.S.
Environmental Protection Agency (EPA)**

Pittsburgh, PA - April 9, 2007 Cellumen, Inc., has signed a multi-year contract with the U.S. Environmental Protection Agency (EPA) to profile potential toxins, the company announced today.

"We are pleased to be selected to participate in the EPA's Toxcast™ program," said Dr. Kate Johnston, Vice President of Discovery Programs at Cellumen. "The goals of this program; to better prioritize environmental chemicals while reducing costs and dependency on animal testing, are perfectly aligned with Cellumen's goals in developing cytotoxicity profiling panels. This project provides a strong opportunity to demonstrate our value for both environmental and pharmaceutical applications."

"This program is an ideal complement to a collaborative program underway with Cambridge HealthTech Associates (CHA) in which Cellumen is providing profiling results to eleven pharmaceutical companies to evaluate how cytotoxicity profiling can be best incorporated into the discovery-development pipeline," Johnston added.

The Cellumen cytotoxicity profiling method measures a full dose response for eleven (11) cellular systems biology parameters at three time points, yielding three hundred and thirty (330) data points for each compound. Advanced informatics tools are then applied to analyze, mine and display the data to identify patterns of activity and provide insights into mechanism of action.

(MORE)

About Cellumen Inc.

Cellumen is the Cellular Systems Biology Company. Cellumen focuses on the cell as an integrated and interacting network of genes, proteins and metabolites responsible for normal and abnormal (disease) function. To promote efficient drug discovery and development, the company offers solutions to the dual challenges of efficacy and toxicity. The company's products and services have application in each of the major segments of the pharmaceutical pipeline: drug discovery ("cellular models of disease"), drug development ("cytotoxicity profiling") and clinical trials ("patient sample profiling"). The Cellumen team leverages its experience and expertise in High Content Screening, cell-based assays, advanced reagents and informatics to create high value solutions. Further information can be found at www.cellumen.com.

####